Functional testing methods for the antiplatelet effects of aspirin (Q37841562)

24 August 2017

1 reference

title

Functional testing methods for the antiplatelet effects of aspirin (English)

1 reference

24 August 2017

1 reference

Karsten Schrör

1

1 reference

24 August 2017

Kurt Huber

series ordinal

2

1 reference

24 August 2017

Thomas Hohlfeld

series ordinal

3

1 reference

24 August 2017

language of work or name

1 reference

1 February 2011

1 reference

24 August 2017

Biomarkers in Medicine

1 reference

24 August 2017

5

1 reference

24 August 2017

1

1 reference

24 August 2017

31-42

1 reference

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

24 August 2017

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Pharmacogenomics in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Scientific and therapeutic advances in antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

The effect of ex vivo anticoagulants on whole blood platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Aspirin resistance: a revival of platelet aggregation tests?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Aspirin non-responder status in patients with recurrent cerebral ischemic attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Methods for the measurement of platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Thromboxane A(2) promotes soluble CD40 ligand release from human platelets.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Variable platelet response to aspirin in patients with ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Differential expression of thromboxane A synthase and prostaglandin H synthase in megakaryocytic cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Smoking alters thromboxane metabolism in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Platelet hyperreactivity and prognosis in survivors of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Pharmacologic inhibition of platelet function: correlation between in vitro tests of platelet function and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Aspirin resistance and adverse clinical events in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Aspirin Resistance in Patients with Stable Coronary Artery Disease with and without a History of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Aspirin resistance - does it clinically matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.122

21 January 2018

Identifiers

DOI

10.2217/BMM.10.122

1 reference

24 August 2017

1 reference